Cis Drug Patent Portfolio
Cis owns 1 orange book drug protected by 3 US patents Given below is the list of Cis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5645815 | Radiolabled compounds for thrombus imaging | 08 Jul, 2014 | Expired |
| US5508020 | Technetium-99M labeled peptides for imaging | 16 Apr, 2013 | Expired |
| US5443815 | Technetium-99m labeled peptides for imaging | 22 Aug, 2012 | Expired |
Cis's Family Patents
Clinical Trials
Recent Clinical Trials by Cis:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain | University of California, San Francisco | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| Peri-operative Oral Pain Control Following Buccal Graft Urethroplasty | University of California, San Francisco | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | Chongqing Precision Biotech Co., Ltd | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | University of California, San Francisco | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Naloxone for Opioid Associated Out of Hospital Cardiac Arrest | University of California, San Francisco | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Inflammatory Challenge and Fear | University of California, San Francisco | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients | University of California, San Francisco | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Chongqing Precision Biotech Co., Ltd | NA |
SUSPENDED
(Sep 1, 2026)
| PHASE1 |
| Understanding Oral Nicotine Pouch Use in Healthy Volunteers | University of California, San Francisco | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | University of California, San Francisco | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | University of California, San Francisco | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction | University of California, San Francisco | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II | University of California, San Francisco | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis | University of California, San Francisco | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2, PHASE3 |
| Dopamine and Sensorimotor Function in Stuttering | University of California, San Francisco | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II | University of California, San Francisco | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study of Oxidative Pathways in MS Fatigue | University of California, San Francisco | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | Chongqing Precision Biotech Co., Ltd | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |
| Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma | University of California, San Francisco | NA |
TERMINATED
(Jul 1, 2026)
| PHASE1 |
| Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | Chongqing Precision Biotech Co., Ltd | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1, PHASE2 |
| buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest | University of California, San Francisco | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | University of California, San Francisco | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest | University of California, San Francisco | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas | University of California, San Francisco | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service | University of California, San Francisco | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma | Beijing Tricision Biotherapeutics Inc | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Providing "Good Sleep" for ICU Sedation | University of California, San Francisco | NA |
TERMINATED
(Jun 1, 2026)
| PHASE1 |
| Sanitation, Water, and Instruction in Face-washing for Trachoma I/II | University of California, San Francisco | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | University of California, San Francisco | NA |
RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy | University of California, San Francisco | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1, PHASE2 |
| FocaL Mass Drug Administration for Vivax Malaria Elimination | University of California, San Francisco | NA |
RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy | University of California, San Francisco | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Naltrexone for Overdose Prevention | University of California, San Francisco | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2, PHASE3 |
| Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A | University of California, San Francisco | NA |
RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Glutide for Ending Methamphetamine | San Francisco Department of Public Health | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Parasitic Ulcer Treatment Trial Pilot | University of California, San Francisco | NA |
COMPLETED
(May 1, 2026)
| PHASE2 |
| Bicalutamide Therapy in Young Women With NAFLD and PCOS | University of California, San Francisco | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |
| Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway | University of California, San Francisco | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE2 |
| Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | University of California, San Francisco | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE2 |
| Embryonal Tumor With Multilayered Rosettes | University of California, San Francisco | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2 |
| Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) | University of California, San Francisco | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |
| BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas | University of California, San Francisco | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE1 |
| Angiotensin II in Liver Transplantation | University of California, San Francisco | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE2, PHASE3 |
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | University of California, San Francisco | NA |
RECRUITING
(Mar 1, 2026)
| PHASE1, PHASE2 |
Cis Drug List
Given below is the complete list of Cis's drugs and the patents protecting them.
1. Acutect
Acutect is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5645815 | Radiolabled compounds for thrombus imaging |
08 Jul, 2014
(12 years ago)
| Expired |
| US5508020 | Technetium-99M labeled peptides for imaging |
16 Apr, 2013
(13 years ago)
| Expired |
| US5443815 | Technetium-99m labeled peptides for imaging |
22 Aug, 2012
(14 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acutect's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List